ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1978

HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis

Irene Lorenzo-Gomez1, Uxia Nogueira-Recalde 2, Natividad Oreiro 3, Jose antonio Pinto-Tasende 4, Francisco J. Blanco 3 and Beatriz Carames 1, 1Grupo de Biología del Cartílago, Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Sergas, A Coruña, Spain, A Coruna, Spain, 2Grupo de Biología del Cartílago, Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Sergas, A Coruña, Spain, A Coruña, Spain, 3Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 4Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruna, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autophagy, Biomarkers and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In osteoarthritis (OA) defects in Autophagy are evident and precede joint damage. Therefore, identifying biomarkers associated with autophagy defects could facilitate the development of personalized therapeutic strategies to prevent OA progression.

Methods: A comparative analysis of 35 autophagy genes was performed in blood from a Prospective OA Cohort of A Coruña (PROCOAC) of non-OA and knee OA patients. Non-OA patients (Age: 61,44 ± 1,16 years; BMI: 25,25 ± 0,52; Females, n=18) and Knee OA patients (Age: 65,50 ± 1,05 years; BMI: 29,55 ± 0,67; Females, n=18, OA grade III-IV) were profiled using an autophagy gene expression array. Confirmatory studies of the candidate genes were performed in blood from Non-OA patients (Age: 60,13 ± 1,12 years; BMI: 24,85 ± 0,59; Sex: Females; n=30) and Knee-OA patients (Age: 68,4 ± 1,11 years; BMI: 29,65 ± 0,55; Females; n=30, OA grade III-IV) by using Taqman Technology. Moreover, the candidate gene was evaluated as a potential biomarker in human cartilage from Normal (n=19) and OA (n=20) patients and in both spontaneous aging (2, 6, 12, 18, and 30 months old, n=3/each time) and surgically-induced OA (10 weeks after surgery, n=4/each) in mice by immunohistochemistry. Remarkably, the consequences of candidate gene silencing on autophagy, FOXO signaling, inflammation, senescence, oxidative stress and cell death by apoptosis was investigated by gene expression and flow cytometry.

Results: 15 autophagy-related genes were downregulated in blood from knee OA patients compared to non-OA patients (p< 0.05). No upregulation was found. although a trend towards upregulation was found for several genes involved in the mTOR signaling pathway. Importantly, key autophagy-related genes, including ATG16L2, ATG12, ATG4B and MAP1LC3B were significant downregulated in knee OA patients (p< 0.05). Interestingly, HSP90AA1 and HSPA8, chaperone-mediated autophagy genes involved in stress response and protein folding, were significant downregulated (p< 0.001). Confirmatory studies for MAP1LC3B and HSP90AA1, showed a significant downregulation (p< 0.001) in blood from knee OA patients. Remarkably, total proteome screening of human OA chondrocytes with defective autophagy, showed a significant reduction of HSP90AA1 (p< 0.05). Moreover, pharmacological inhibition of HSP90 chaperone reduces chondrocyte homeostasis.  Remarkably, HSP90AA1 expression was reduced in OA cartilage (p < 0.01) and in spontaneous aging and surgically-induced OA in mice (p< 0.05). Interestingly, HSP90AA1 silencing increased LC3 and FOXO1 expression (p < 0.01) and increased NFkB and p16 expression (p< 0.05) at 48h post-transfection. In addition, HSP90AA1 silencing increased cell death by apoptosis and mitochondrial ROS production 72h post-transfection (p < 0.05). These data indicate that HSP90AA1 might be a potential biomarker associated with defective autophagy in OA.

Conclusion: We identified biomarkers of defective autophagy as a mechanism of central homeostasis, which gives us a general vision of the disease mechanisms linked to OA clinical reality.


Disclosure: I. Lorenzo-Gomez, None; U. Nogueira-Recalde, None; N. Oreiro, None; J. Pinto-Tasende, None; F. Blanco, None; B. Carames, None.

To cite this abstract in AMA style:

Lorenzo-Gomez I, Nogueira-Recalde U, Oreiro N, Pinto-Tasende J, Blanco F, Carames B. HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/hsp90aa1-a-chaperone-mediated-autophagy-mediator-is-a-biomarker-of-joint-damage-in-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hsp90aa1-a-chaperone-mediated-autophagy-mediator-is-a-biomarker-of-joint-damage-in-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology